

Emily Tarsell, LCPC, LCPAT

**2314 Benson Mill Road
Sparks, Maryland 21152**

Opposed to SB 736

March 2, 2021

Good afternoon Chair, Vice Chair and Senators,

I am Emily Tarsell and I oppose SB736 because it is unnecessary and dangerous. Unnecessary because childhood and teen vaccination rates are already between 90 and 99%, except for the HPV vaccine. Dangerous because it irresponsibly disregards a child's unique health history, disregards parental consent, disregards the primary care provider, disregards informed consent and disregards responsible administration of vaccines.

Regarding the HPV vaccine, it is one about which I know a lot since researching it following my sweet daughter's death-by-Gardasil vaccination in 2008. I learned too late that there is no evidence that the vaccine prevents any cancer cervical or otherwise, that hpvs clear on their own 95% of the time, that rates of all hpv related cancers in the US are extremely low (less than 1%) and that my daughter never was at risk of getting cervical cancer as long as she did regular pap screening. She was the 23rd death reported and now there are more than 525 deaths and 10,000 seriously injured youth. Think about that. Thousands of youth who were misled to believe they were going to protect themselves who ended up with crippling disabilities or death from a vaccine with no proven benefit.

In March 2018 I attended a meeting called "*HPV Vaccination Symposium, Providers are the Key.*" The message presented there by the MD DOH was NOT about safety or effectiveness, but all about increasing uptake for this lucrative vaccine. Providers were coached how to assertively and deceptively push the vaccine and bribe or shame staff into increasing uptake for bonuses.

It seems pharmacists want in on the Gardasil gravy train, consequences be damned. Please protect our children and veto this reckless bill. Thank you.

Emily Tarsell

References:

1. Dhar A. Groups write to Azad on HPV vaccine trial. The Hindu. April 8, 2010. <http://beta.thehindu.com/news/national/article392111.ece>. Accessed April 30, 2011.
2. Sarojini NB, Srinivasan S, Madhavi Y, et al. The HPV vaccine: science, ethics and regulation. *Econom Polit Weekly*. 2010; 45 (48): 27034. January 3, 2011.
- 3 Erickson N. Japan and the hpv vaccine controversy. www.sanevax.org. Accessed 4/29/2014.

4. Kyodo. Cervarix vaccine issues trigger health notice. *Japan Times*. June 15, 2013. <http://www.japantimes.co.jp/news/2013/06/15/national/cervix-vaccine-issues-trigger-health-notice/#.VMfXIWjF8fX>. Accessed 4/29/2014.
5. Ministry of Health, Labor and Welfare. Shimbun A. Analysis: Experts at loss over pain from cervical cancer vaccination. *Asia and Japan Watch*. June 18, 2013. http://ajw.asahi.com/article/behind_news/social_affairs/AJ201306180057. Accessed 1/27/15
6. Archive of proceedings and events regarding an investigation into hpv vaccines safety and efficacy by the Japanese Ministry of Health, Labor and Welfare. *Medwatcher Japan*. <http://www.yakugai.gr.jp/en/activity/index.php?year=2014>. Accessed 1/26/15.
7. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. *JAMA*. 2009; 302 (7): 750-757.
8. Tomljenovic L, Wilyman J, Vanamee E, Bark T, Shaw CA. HPV vaccines and cancer prevention, science versus activism. *Infectious Agents and Cancer* 2013,8:6. <http://www.infectagentscancer.com/content/8/1/6>.
9. See the rulings from Judge Coster Williams and Special Master Moran. www.gardasil-and-unexplained-deaths.com. Accessed 4/12/2018.
10. <https://wonder.cdc.gov/controller/datarequest/D8>. Data search. Accessed April 15, 2018.
11. Gardasil, Publication 9883611. (2008). Merck and Co., Inc. Whitehouse Station, NJ 08889, USA.
12. <https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm426457.pdf> Package insert for Gardasil 96.
13. <https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm111263.pdf> Package insert for Gardasil
14. Tomljenovic L, Shaw CA, Spinosa JP: Human Papillomavirus (HPV) Vaccines as an option for preventing cervical malignancies: (How) effective and safe? *Curr Pharm Des* 2012, :CPD-EPUB-20120924-13. Epub ahead of print.
15. Tomljenovic L, Shaw CA: Who profits from uncritical acceptance of biased estimates of vaccine efficacy and safety? *Am J Public Health* 2012, 102(9):e13–e14.
16. Tomljenovic L, Shaw CA: Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds? *Ann Med* 2011, doi:10.3109/07853890.2011.645353
17. Haug C. The risks and benefits of HPV vaccination. *JAMA*. 2009; 302 (7): 795-796.
18. Lee SH. The truth about HPV. *Bottom Line Health*. April 2011: 9-11.
19. Legifrance gov. Le Service Public De La Diffusion Du Droit. Decision du 31 aout 2010 interdisant une publicite pour un medicament mentionnee a l'article L. 5122-1, premier alinea, du code de la sante publique destinee aux personnes habilees a prescrire ou delivrer ces medicaments ou a les utiliser dans l'exercice de leur art. <http://www.legifrance.gouv.fr/affichTexte.do;jsessionid=?cidTexte=JORFTEXT000022839429&dateTexte&oldAction=rechJO&categorieLien=id>. Accessed Feb 3, 2011.
20. Dhar A. Groups write to Azad on HPV vaccine trial. *The Hindu*. April 8, 2010. <http://beta.thehindu.com/news/national/article392111.ece>. Accessed April 30, 2011.
21. Sarojini NB, Srinivasan S, Madhavi Y, et al. The HPV vaccine: science, ethics and regulation. *Econom Polit Weekly*. 2010; 45 (48): 27034. January 3, 2011.

22. Erickson N. Japan and the hpv vaccine controversy. www.sanevax.org. Accessed 4/29/2014.
23. Merck. Package Leaflet: Information for the User. Gardasil. msd-info@merck.com. Revised January 2017. Accessed 7/25/17.
24. Harper DM, Williams KB. Prophylactic HPV vaccines: current knowledge of impact on gynecologic pre-malignancies. *Discov Med* 2010; **10**: 7-17.
25. Tomljenovic L, Shaw CA. No autoimmune safety signals after vaccination with quadrivalent HPV vaccine Gardasil? *Journal of Internal Medicine*: 2012,272; 514-515.
26. Newton, David E. (2013). *Vaccination Controversies*. ABC-CLIO. pp.137–141. ISBN 978-1-61069-311-0.
27. American Cancer Society (2015a). *Cancer Facts and Figures*. 2015. Atlanta, GA. American Cancer Society, Inc. [online] <http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf>. Accessed January 9, 2015
28. American Cancer Society. Cervical cancer prevention and early detection. <http://www.cancer.org/cancer/cervical-cancer/prevention-and-early-detection/cervical-cancer-be-prevented.html>. Accessed 11/19/2017.
29. American Cancer Society. Cervical cancer. <https://www.cancer.org/cancer/cervical-cancer/about/key-statistics.html>. Accessed 11/16/2017.
30. American Cancer Society. Vaginal cancer. Early detection, diagnosis and staging. <https://www.cancer.org/cancer/vaginal-cancer/detection-diagnosis-staging.html>. Accessed 11/16/17.
31. American Cancer Society. Vulvar cancer. Causes, risk factors and prevention. <https://www.cancer.org/cancer/vulvar-cancer/causes-risks-prevention.html> Accessed 11/16/17.
32. Centers for Disease Control and Prevention. Gynecologic cancers. <https://www.cdc.gov/cancer/vagvulv/statistics/index.htm>. Accessed 11.16.2017.
33. American Cancer Society. About penile cancer. <https://www.cancer.org/cancer/penile-cancer/about/key-statistics.html>. Accessed 11/16/2017. rare.
34. American Cancer Society. Cancer statistics center. https://cancerstatisticscenter.cancer.org/?_ga=2.243533964.828374716.1510883066-1015895049.1510883066#! , Accessed 11/16/2017.